中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (3): 187-195.doi: 10.35541/cjd.20210698
《脓疱型银屑病诊疗中国专家共识(2022版)》编写委员会专家组
收稿日期:
2021-09-24
修回日期:
2021-11-30
发布日期:
2022-03-03
通讯作者:
史玉玲;顾军;郑志忠
E-mail:shiyuling1973@tongji.edu.cn;gujun79@163.com;zhengzhizhong@medmail.com
基金资助:
Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”
Received:
2021-09-24
Revised:
2021-11-30
Published:
2022-03-03
Contact:
Shi Yuling; Gu Jun; Zheng Zhizhong
E-mail:shiyuling1973@tongji.edu.cn;gujun79@163.com;zhengzhizhong@medmail.com
Supported by:
摘要: 【摘要】 脓疱型银屑病是银屑病的特殊类型,临床表现以红斑基础上的无菌性脓疱为特征,病因涉及遗传、免疫及感染等多种因素。脓疱型银屑病分为局限性和泛发性两个主要亚型。局限性脓疱型银屑病以外用药物治疗为主,疗效欠佳者可采用系统治疗和光疗;泛发性脓疱型银屑病通常需要系统治疗,可联合外用药物治疗和光疗。在国内外最新指南及共识的基础上,结合我国的诊疗现状,本专家委员会重点在脓疱型银屑病的临床表现及分型、辅助检查、诊断标准和治疗等方面形成共识,以进一步形成规范化诊疗模式。
. 脓疱型银屑病诊疗中国专家共识(2022版)[J]. 中华皮肤科杂志, 2022,55(3):187-195. doi:10.35541/cjd.20210698
Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022)[J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.doi:10.35541/cjd.20210698
[1] | 全国银屑病流行调查组. 全国1984年银屑病流行调查报告[J]. 中华皮肤科杂志, 1986,19(5):253⁃261. |
[2] | Feng JN, Guo JZ, Zhang Q, et al. Epidemiology and disease burden of GPP in urban China from 2012 to 2016 and a systematic review[C/OL]//e⁃Poster at EADV 30th congress. 2021[2021⁃09⁃29]. https://www.eadvcongress2021.org/index.php/home/scientific/scientific⁃programme. |
[3] | Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background[J]. Acta Derm Venereol, 1996,76(1):68⁃71. doi: 10.2340/00015555766871. |
[4] | Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey[J]. Eur J Dermatol. 2006,16(6):669⁃673. |
[5] | Ayala⁃Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases[J]. Psoriasis (Auckl), 2016,6:7⁃32. doi: 10.2147/PTT.S64950. |
[6] | Li X, Chen M, Fu X, et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris[J]. J Dermatol Sci, 2014,76(2):132⁃138. doi: 10.1016/j.jdermsci.2014.08.007. |
[7] | Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin⁃36 signalling in plaque psoriasis and pustular psoriasis[J]. Acta Derm Venereol, 2018,98(1):5⁃13. doi: 10.2340/00015555⁃2808. |
[8] | Körber A, Mössner R, Renner R, et al. Mutations in IL36RN in patients with generalized pustular psoriasis[J]. J Invest Dermatol, 2013,133(11):2634⁃2637. doi: 10.1038/jid.2013.214. |
[9] | Qin P, Zhang Q, Chen M, et al. Variant analysis of CARD14 in a Chinese Han population with psoriasis vulgaris and generalized pustular psoriasis[J]. J Invest Dermatol. 2014,134(12):2994⁃2996. doi: 10.1038/jid.2014.269. |
[10] | Li L, You J, Fu X, et al. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population[J]. Br J Dermatol, 2019,180(2):425⁃426. doi: 10.1111/bjd.17392. |
[11] | Fu F, Sun Y, Zhao Q, et al. Rare CARD14 missense variants associated with palmoplantar pustulosis (PPP) in the Chinese Han population[J]. Eur J Dermatol, 2019,29(1):99⁃100. doi: 10.1684/ejd.2018.3457. |
[12] | Johnston A, Xing X, Wolterink L, et al. IL⁃1 and IL⁃36 are dominant cytokines in generalized pustular psoriasis[J]. J Allergy Clin Immunol, 2017,140(1):109⁃120. doi: 10.1016/j.jaci.2016.08.056. |
[13] | Pfaff CM, Marquardt Y, Fietkau K, et al. The psoriasis⁃associated IL⁃17A induces and cooperates with IL⁃36 cytokines to control keratinocyte differentiation and function[J]. Sci Rep, 2017,7(1):15631. doi: 10.1038/s41598⁃017⁃15892⁃7. |
[14] | Arakawa A, Vollmer S, Besgen P, et al. Unopposed IL⁃36 activity promotes clonal CD4(+) T⁃cell responses with IL⁃17A production in generalized pustular psoriasis[J]. J Invest Dermatol, 2018,138(6):1338⁃1347. doi: 10.1016/j.jid.2017.12. 024. |
[15] | Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis ⁃ a model disease for specific targeted immunotherapy, systematic review[J]. Exp Dermatol, 2018,27(10):1067⁃1077. doi: 10.1111/exd.13699. |
[16] | Murakami M, Terui T. Palmoplantar pustulosis: current understanding of disease definition and pathomechanism[J]. J Dermatol Sci, 2020,98(1):13⁃19. doi: 10.1016/j.jdermsci.2020. 03.003. |
[17] | Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis[J]. J Eur Acad Dermatol Venereol, 2017,31(11):1792⁃1799. doi: 10.1111/jdv. 14386. |
[18] | 秦万章,顾军. 银屑病学[M]. 南京: 江苏凤凰科学技术出版社, 2020. |
[19] | 中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018完整版)[J]. 中华皮肤科杂志, 2019,52(10):667⁃710. doi: 10.35541/cjd.20190847. |
[20] | Sugiura K, Nakasuka A, Kono H, et al. Impetigo herpetiformis with IL36RN mutations in a Chinese patient: a founder haplotype of c.115+6T>C in East Asia[J]. J Dermatol Sci, 2015,79(3):319⁃320. doi: 10.1016/j.jdermsci.2015.06.003. |
[21] | Sugiura K, Oiso N, Iinuma S, et al. IL36RN mutations underlie impetigo herpetiformis[J]. J Invest Dermatol, 2014,134(9):2472⁃2474. doi: 10.1038/jid.2014.177. |
[22] | Wang Q, Liu W, Zhang L. Clinical features of von Zumbusch type of generalized pustular psoriasis in children: a retrospective study of 26 patients in southwestern China[J]. An Bras Dermatol, 2017,92(3):319⁃322. doi: 10.1590/abd1806⁃4841.20175536. |
[23] | Owczarczyk⁃Saczonek A, Znajewska⁃Pander A, Owczarek W, et al. Clinicopathologic retrospective analysis of annular pustular psoriasis[J]. Acta Dermatovenerol Alp Pannonica Adriat, 2018,27(4):215⁃219. |
[24] | Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes[J]. J Allergy Clin Immunol, 2019,143(3):1021⁃1026. doi: 10.1016/j.jaci.2018. 06.038. |
[25] | Zelickson BD, Muller SA. Generalized pustular psoriasis. A review of 63 cases[J]. Arch Dermatol, 1991,127(9):1339⁃45. PMID: 1892402. |
[26] | Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP[J]. J Dermatol, 2018,45(11):1235⁃1270. doi: 10.1111/1346⁃8138.14523. |
[27] | Bhushan M, Burden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double⁃blind, placebo⁃controlled study[J]. Br J Dermatol, 2001,145(4):546⁃553. doi: 10.1046/j.1365⁃2133.2001.04411.x. |
[28] | Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation[J]. J Am Acad Dermatol, 2012,67(2):279⁃288. doi: 10.1016/j.jaad.2011.01.032. |
[29] | Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies[J]. Clin Rev Allergy Immunol, 2018,54(1):102⁃113. doi: 10.1007/s12016⁃018⁃8668⁃1. |
[30] | Rueda⁃Gotor J, González⁃Gay MA, Blanco Alonso R, et al. Successful effect of tocilizumab in anti⁃TNF⁃α⁃induced palmoplantar pustulosis in rheumatoid arthritis[J]. Joint Bone Spine, 2012,79(5):510⁃513. doi: 10.1016/j.jbspin.2012.06.010. |
[31] | Wilsmann⁃Theis D, Jacobi A, Frambach Y,et al. Palmoplantar pustulosis⁃ a cross⁃sectional analysis in Germany[J]. Dermatol Online J, 2017,23(4):13030/qt0h15613d. doi: 10.5070/D32340 34627. |
[32] | Sehgal VN, Verma P, Sharma S, et al. Acrodermatitis continua of Hallopeau: evolution of treatment options[J]. Int J Dermatol, 2011,50(10):1195⁃1211. doi: 10.1111/j.1365⁃4632.2011.04993.x. |
[33] | Soleymani T, Vassantachart JM, Wu JJ. Comparison of guidelines for the use of cyclosporine for psoriasis: a critical appraisal and comprehensive review[J]. J Drugs Dermatol, 2016,15(3):293⁃301. PMID: 26954314. |
[34] | Sheu JS, Divito SJ, Enamandram M, et al. Dapsone therapy for pustular psoriasis: case series and review of the literature[J]. Dermatology,2016,232(1):97⁃101. doi: 10.1159/000431171. |
[35] | Ji YZ, Geng L, Ma XH, et al. Severe generalized pustular psoriasis treated with mycophenolate mofetil[J]. J Dermatol, 2011,38(6):603⁃605. doi: 10.1111/j.1346⁃8138.2010.01019.x. |
[36] | Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis[J]. Expert Opin Drug Saf, 2020,19(8):969⁃980. doi: 10.1080/14740338.2020.1785427. |
[37] | Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin⁃1⁃receptor antagonist Anakinra: lack of correlation with IL1RN mutations[J]. Ann Intern Med, 2010,153(1):66⁃67. doi: 10.7326/0003⁃4819⁃153⁃1⁃201007060⁃00030. |
[38] | Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin⁃36 pathway for the treatment of generalized pustular psoriasis[J]. N Engl J Med, 2019,380(10):981⁃983. doi: 10. 1056/NEJMc1811317. |
[39] | Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double⁃blind, placebo⁃controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare[J]. BMJ Open, 2021,11(3):e043666. doi: 10.1136/bmjopen⁃2020⁃043666. |
[40] | Hervé Bachelez, Siew⁃Eng Choon, Slaheddine Marrakchi, et al. Trial of spesolimab for generalized pustular psoriasis[J]. N Engl J Med, 2021,385(26):2431⁃2440. doi: 10.1056/NEJMoa2111563. |
[41] | Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real⁃life experience[J]. Ther Adv Chronic Dis, 2018,9(8):147⁃158. doi: 10.1177/2040622318772705. |
[42] | Kurizky PS, Ferreira Cde C, Nogueira LS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding[J]. An Bras Dermatol, 2015,90(3):367⁃375. doi: 10.1590/abd1806⁃4841.20153113. |
[43] | Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients[J]. Joint Bone Spine, 2016,83(3):341⁃343. doi: 10.1016/j.jbspin.2015.07.004. |
[44] | Eworuke E, Panucci G, Goulding M, et al. Use of tumor necrosis factor⁃alpha inhibitors during pregnancy among women who delivered live born infants[J]. Pharmacoepidemiol Drug Saf, 2019,28(3):296⁃304. doi: 10.1002/pds.4695. |
[45] | Posso⁃De Los Rios CJ, Pope E, Lara⁃Corrales I. A systematic review of systemic medications for pustular psoriasis in pediatrics[J]. Pediatr Dermatol, 2014,31(4):430⁃439. doi: 10. 1111/pde.12351. |
[46] | Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents ⁃ Short version part 2[J]. J Dtsch Dermatol Ges, 2019,17(9):959⁃973. doi: 10.1111/ddg.13936. |
[47] | Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents ⁃ Short version part 1[J]. J Dtsch Dermatol Ges, 2019,17(8):856⁃870. doi: 10.1111/ddg.13907. |
[48] | Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis[J]. Expert Rev Clin Immunol, 2019,15(9):907⁃919. doi: 10.1080/1744666X.2019.1648209. |
[49] | Bachelez H. Pustular psoriasis: the dawn of a New Era[J]. Acta Derm Venereol, 2020,100(3):adv00034. doi: 10.2340/00015555⁃3388. |
[50] | Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis⁃⁃most common form of pustular psoriasis in children: report of three cases and review of the literature[J]. Pediatr Dermatol, 2002,19(1):19⁃25. doi: 10.1046/j.1525⁃1470.2002. 00026.x. |
[51] | Brunasso A, Massone C. Recent advances in palmoplantar pustulosis[J]. Fac Rev, 2021,10:62. doi: 10.12703/r/10⁃62. |
[52] | Kromer C, Loewe E, Schaarschmidt ML, et al. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients[J]. J Dermatol, 2020,47(9):989⁃997. doi: 10.1111/1346⁃8138. 15466. |
[1] | 孙小洁 刘毅. 抗雄激素药物治疗皮肤病研究进展[J]. 中华皮肤科杂志, 2023, 56(9): 882-885. |
[2] | 王钰倩 乔建军 方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2023, 56(9): 885-888. |
[3] | 刘元香 梁源 赵欣荣 孙玉娟 马琳 徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023, 56(9): 849-852. |
[4] | 刘小扬 赵琰 蔡林 张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848. |
[5] | 付丹丹 李佳林 付修宇 张芯育 胡华 宋向凤 田中伟. S100A10蛋白在银屑病皮损的表达及对小鼠银屑病样皮炎模型的影响[J]. 中华皮肤科杂志, 2023, 56(9): 839-844. |
[6] | 袁心刚 倪思利 张建 罗晓燕 王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786. |
[7] | 钟洁敏 邵蕾 梁毅敏 黄琼霄 夏曼琪 刘玉梅. 射频火针与光动力疗法治疗面部中重度痤疮炎性皮损的疗效与安全性对比研究[J]. 中华皮肤科杂志, 2023, 56(8): 751-755. |
[8] | 中国医师协会皮肤科医师分会. [开放获取] 保湿润肤类产品应用指导专家共识(2023版)[J]. 中华皮肤科杂志, 2023, 56(8): 711-717. |
[9] | 宋志强 陈奇权 葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723. |
[10] | 王俊霞 郭伟楠 陈慧 郝军峰 李冰 卫静宜 赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765. |
[11] | 陈小敏 张景展 丁媛 康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802. |
[12] | 周彤 耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793. |
[13] | 李越 吴金燕 袁若月 杨屈杨 赵贤省 朱宁文. 细胞治疗遗传性大疱性表皮松解症研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 698-702. |
[14] | 蒋晓妍 高敏 张晓艳 刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692. |
[15] | 唐志铭 荆梦晴 陆鹭 单霄 张翠侠 张晓宇 孟飒. 犀地凉血方通过LncRNA NEAT1/miR-485-5p/ STAT3调控网络对HaCaT细胞增殖、凋亡影响的研究[J]. 中华皮肤科杂志, 2023, 56(7): 642-650. |
|